Effects of N-Rydroxy-N'-aminoguanidine Isoquinoline in Combination With Other Inhibitors of Ribonucleotide Reductase on L1210 Cells
- 1 June 1988
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 80 (7) , 491-496
- https://doi.org/10.1093/jnci/80.7.491
Abstract
The 1-isoquinolylmethylene derivative of N′-hydroxy-N′-aminoguanidine (HAG) is the most potent agent of the recently synthesized series of HAG-derived ribonucleotide reductase inhibitors. To potentiate the effects of the HAG-isoquinoline drug [HAG-l-isoquinolylmethylene tosylate (HAG-IQ)], we combined it with other inhibitors of ribonucleotide reductase. Using mouse leukemia L1210 cell cultures, we tested drug combinations for their cytostatic and cytotoxic properties and for their effects on intracellular ribonucleotide reductase activity and nucleic acid synthesis. Deoxyguanosine or deoxyadenosine combined with HAG-IQ inhibited cell growth in an additive manner; three-drug combinations, HAG-IQ plus either deoxy-guanosine/8-aminoguanosine or deoxyadenosine/deoxy-coformycin, were strongly synergistk. When Desferal, an iron chelator, was added to these combinations, the four-drug combinations increased inhibition of cell growth and increased cytotoxicity. The intracellular target of these drug combinations in L1210 cells was the ribonucleotide reductase site. The formation of deoxycytidine from [14C]cytidine and incorporation into DNA were markedly inhibited by these drug combinations, while RNA synthesis was unaffected. These data show that the antiproliferative and cytotoxic effects of HAG-IQ, a potent inhibitor by itself, can be further potentiated in combinations with other ribonucleotide reductase inhibitors. [J Natl Cancer Inst 1988;80:491–496]Keywords
This publication has 12 references indexed in Scilit:
- Altered expression of ribonucleotide reductase and role ofM2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell linesSomatic Cell and Molecular Genetics, 1987
- EFFECTS OF N-HYDROXY-N'-AMINOGUANIDINE DERIVATIVES ON RIBONUCLEOTIDE REDUCTASE-ACTIVITY, NUCLEIC-ACID SYNTHESIS, CLONOGENICITY, AND CELL-CYCLE OF L1210 CELLS1987
- FOLINIC ACID AUGMENTATION OF THE EFFECTS OF FLUOROPYRIMIDINES ON MURINE AND HUMAN-LEUKEMIC CELLS1986
- Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N′-aminoguanidine derivativesBiochemical Pharmacology, 1985
- SYNERGISTIC INHIBITION OF LEUKEMIA-L1210 CELL-GROWTH INVITRO BY COMBINATIONS OF 2-FLUOROADENINE NUCLEOSIDES AND HYDROXYUREA OR 2,3-DIHYDRO-1H-PYRAZOLE[2,3-A]IMIDAZOLE1984
- RAPID ASSAY FOR EVALUATING THE CHEMOSENSITIVITY OF HUMAN-TUMORS IN SOFT AGAR CULTURE1982
- EFFECTS OF COMBINATIONS OF DRUGS HAVING DIFFERENT MODES OF ACTION AT THE RIBONUCLEOTIDE REDUCTASE SITE ON GROWTH OF L1210-CELLS IN CULTURE1982
- Inhibitors of purine nucleoside phosphorylaseBiochemical Pharmacology, 1982
- Effect of iron-chelating agents on inhibitors of ribonucleotide reductaseBiochemical Pharmacology, 1981
- Adenosine deaminase impairment and ribonucleotide reductase activity and levels in HeLa cells.Journal of Biological Chemistry, 1980